1. Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective.
- Author
-
Zhang Y, Chamblee M, Xu J, Qu P, Shamseldin MM, Yoo SJ, Misny J, Thongpan I, Kc M, Hall JM, Gupta YA, Evans JP, Lu M, Ye C, Hsu CC, Liang X, Martinez-Sobrido L, Yount JS, Boyaka PN, Liu SL, Dubey P, Peeples ME, and Li J
- Subjects
- Animals, Female, Mice, Cricetinae, Humans, Measles-Mumps-Rubella Vaccine immunology, Measles-Mumps-Rubella Vaccine administration & dosage, Measles virus immunology, Measles virus genetics, Immunoglobulin G blood, Immunoglobulin G immunology, Mumps virus immunology, Mumps virus genetics, Mice, Knockout, Mesocricetus, Immunoglobulin A immunology, Immunoglobulin A blood, Spike Glycoprotein, Coronavirus immunology, Spike Glycoprotein, Coronavirus genetics, Administration, Intranasal, SARS-CoV-2 immunology, SARS-CoV-2 genetics, COVID-19 prevention & control, COVID-19 immunology, COVID-19 virology, Antibodies, Viral immunology, Antibodies, Viral blood, Antibodies, Neutralizing immunology, Antibodies, Neutralizing blood, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage
- Abstract
As the new SARS-CoV-2 Omicron variants and subvariants emerge, there is an urgency to develop intranasal, broadly protective vaccines. Here, we developed highly efficacious, intranasal trivalent SARS-CoV-2 vaccine candidates (TVC) based on three components of the MMR vaccine: measles virus (MeV), mumps virus (MuV) Jeryl Lynn (JL1) strain, and MuV JL2 strain. Specifically, MeV, MuV-JL1, and MuV-JL2 vaccine strains, each expressing prefusion spike (preS-6P) from a different variant of concern (VoC), were combined to generate TVCs. Intranasal immunization of IFNAR1
-/- mice and female hamsters with TVCs generated high levels of S-specific serum IgG antibodies, broad neutralizing antibodies, and mucosal IgA antibodies as well as tissue-resident memory T cells in the lungs. The immunized female hamsters were protected from challenge with SARS-CoV-2 original WA1, B.1.617.2, and B.1.1.529 strains. The preexisting MeV and MuV immunity does not significantly interfere with the efficacy of TVC. Thus, the trivalent platform is a promising next-generation SARS-CoV-2 vaccine candidate., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF